Recursion Pharmaceuticals (RXRX) Current Leases (2022 - 2026)

Recursion Pharmaceuticals' Current Leases history runs 5 years deep, the most recent figure standing at $13.1 million for Q1 2026.

• Quarterly Current Leases rose 10.41% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (up 10.41% YoY) and the FY2025 annual result came in at $12.7 million, down 8.21% from the prior year.
• Current Leases was $13.1 million for Q1 2026 at Recursion Pharmaceuticals, up from $12.7 million in the prior quarter.
• Across five years, Current Leases topped out at $13.8 million in Q4 2024 and bottomed at $4.1 million in Q1 2022.
• A 5-year average of $8.2 million and a median of $6.1 million in 2023 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases surged 125.56% — and 2025, when it fell 8.21%.
• Recursion Pharmaceuticals' Current Leases stood at $6.0 million in 2022, then increased by 2.76% to $6.1 million in 2023, then jumped by 125.56% to $13.8 million in 2024, then slipped by 8.21% to $12.7 million in 2025, then increased by 3.35% to $13.1 million in 2026.
• Business Quant data shows RXRX's Current Leases at $13.1 million in Q1 2026, $12.7 million in Q4 2025, and $11.5 million in Q3 2025.